GlassScriptPhysician profile
Louis C W Jan
NPI 1831152966
$25,460.94
in general payments reported to CMS, 2019-2025
29 companies · $3,426 in 2025
The $3,426 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $3,818 · 2021: $685 · 2022: $6,437 · 2023: $6,884 · 2024: $3,375 · 2025: $3,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,865 · Consulting Fee: $6,661 · Education: $106 · Travel and Lodging: $52.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,865.11 |
| Consulting Fee | $6,661.18 |
| Education | $105.59 |
| Travel and Lodging | $52.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $6,351.70 | 2022-2025 | Bexsero, Benlysta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $3,070.05 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $2,998.31 | 2021-2025 | |
| Horizon Therapeutics Plc | $2,657.23 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $2,200.61 | 2022-2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,803.87 | 2020 | |
| Amgen INC. | $1,280.60 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Vifor Pharma, INC. | $1,120.64 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $868.28 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $517.77 | 2023-2025 | Filspari |
| Ardelyx, INC. | $464.24 | 2025 | Xphozah 30 Mg, Ibsrela |
| Fresenius USA Marketing, INC. | $308.27 | 2019-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.60 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $253.06 | 2019-2025 | Auryxia, Vafseo |
| Aurinia Pharma U.S., INC. | $245.02 | 2021-2025 | Lupkynis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $223.46 | 2023-2025 | |
| Novo Nordisk INC | $168.16 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $142.03 | 2025 | Zepbound, Mounjaro |
| Abbvie INC. | $120.76 | 2024 | |
| Ani Pharmaceuticals, INC. | $91.70 | 2023-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $79.99 | 2024 | Soliris |
| Nxstage Medical, INC. | $77.98 | 2025 | Nxstage System One |
| Mallinckrodt Hospital Products INC. | $30.15 | 2024 | Terlivaz, Acthar |
| Recor Medical INC | $20.73 | 2025 | Paradise Ultrasound Renal Denervation System |
| Kyowa Kirin, INC. | $18.47 | 2025 | |
| Janssen Pharmaceuticals, INC | $18.40 | 2019 | |
| Opko Pharmaceuticals, LLC | $14.69 | 2022 | |
| Renalytix Ai, INC. | $13.51 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Mallinckrodt Enterprises LLC | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Jan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.